Search

Your search keyword '"Moioli MC"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Moioli MC" Remove constraint Author: "Moioli MC"
84 results on '"Moioli MC"'

Search Results

1. Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals

2. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

4. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART

7. PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS

8. PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS

10. Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection

11. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

12. Cell-of-Origin Identification and Prognostic Correlation in HIV-Associated Diffuse Large B-Cell Lymphomas: Results of an Italian Multicentric Study

13. Incidence of Malignancies in HIV‐Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study

14. Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection

15. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study

16. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

17. A Comparison between Abacavir and Efavirenz as the Third Drug Used in Combination with a Background Therapy Regimen of 2 Nucleoside Reverse‐Transcriptase Inhibitors in Patients with Initially Suppressed Viral Loads

18. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort

19. Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008

20. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

21. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

22. Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women: Data From the ICONA Foundation Study Group, Years 1997-2013

23. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure

24. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort

25. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count

26. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure

27. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

28. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study

29. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients

30. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

31. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures

32. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

33. Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting

34. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis

35. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina

36. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

37. Genetic polymorphisms differently influencing the emergence of atrophy and fataccumulation in HIV-related lipodystrophy

38. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

39. Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis

41. Evolution of HVR-1 Quasispecies after 1-Year Treatment in HIV/HCV-Coinfected Patients According to the Pattern of Response to Highly Active Antiretroviral Therapy

42. Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals

43. The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?

44. Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems

45. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals

46. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

47. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

48. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

49. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus

50. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation

Catalog

Books, media, physical & digital resources